Zobrazeno 1 - 10
of 137
pro vyhledávání: '"I, Hindy"'
Autor:
S. Eckhardt, M. Nekulova, Z. Mechl, I. Hindy, R. Tomek, J. Röthig, F. Gyergyay, K. Kolaric, Decker A, I. Sawinsky, S. Kerpel-Fronius
Publikováno v:
European Journal of Haematology. 38:67-69
SUMMARY Twenty-five breast cancer patients previously not exposed to adriamycin, were treated with 30 mg/m2/day aclarubicin for four consecutive days. Out of the 19 evaluable cases 1 CR and 2 PR were observed giving an overall remission rate of 16%.
Autor:
R. Valavaara, I. Nilsson, O Mella, G. Westman, H. Modig, Guillermo Blanco, M Pawlicki, A. Hajba, Seppo Pyrhönen, T Pienkowski, I Hindy, J Bauer, Stein Gundersen, S Lundgren, T Hietanen, J Vuorinen
Publikováno v:
British Journal of Cancer
The study was planned to compare, in a prospective double-blind randomized trial, the efficacy and safety of toremifene (TOR) and tamoxifen (TAM) in post-menopausal patients with advanced breast cancer who have not had prior systemic therapy for adva
Publikováno v:
Oncology. 47:84-86
Double (kappa + lambda), Bence Jones (BJ) proteinuria was detected in a male patient of 73 years. The disease started as a solitary plasmacytoma in bone and transformed into multiple myeloma. At the beginning, isolated BJ lambda proteinuria was obser
Publikováno v:
European journal of cancer (Oxford, England : 1990). (2)
In a combined phase I-II study, the hormonal effects of toremifene (TOR) were investigated in 30 patients. Half of the patients received continuous therapy of TOR 60 mg and half 300 mg of TOR orally daily. Serum concentrations of oestradiol (E2), pro
Publikováno v:
Acta medica Hungarica. 50(3-4)
One hundred ninety patients with germ cell line testicular tumours were treated according to the modified Einhorn scheme. The response rate was 67.9%. The most favourable results were found in the embryonal histologic type (RR = 76.9%) in the biologi
Publikováno v:
Orvosi hetilap. 132(13)
In a combined phase I-II study the hormonal effects of Toremifene were investigated in 15-15 patients at two dose levels: 60 mg and 300 mg per os, daily. Serum estradiol, progesterone, testosterone, follicle-stimulating hormone, luteinizing hormone,
Publikováno v:
Journal of steroid biochemistry. 36(3)
Toremifene, an antiestrogenic drug administered at three dose levels (60, 120, and 300 mg/day) was investigated in 17 postmenopausal patients with advanced breast cancer previously treated with hormonal and/or cytostatic therapy. The drug proved to b
Autor:
S. Kerpel-Fronius, A. Hajba, Matti Grönroos, B. Vincze, I. Számel, J. Mäenpää, I. Hindy, Lauri Kangas, H. Sundquist, S. Eckhardt
Publikováno v:
Journal of steroid biochemistry. 36(3)
The effect of toremifene treatment on the serum levels of sex steroids (estradiol, progesterone, testosterone), FSH, LH, prolactin, TSH, T3, T4 and SHBG was investigated. Basal prolactin level and the “prolactin reserve capacity” of the hypophysi
Publikováno v:
Neoplasma. 37(4)
Between December 1979 and July 1986, 190 patients with nonseminomatous germ-cell testicular tumors were treated according to the modified Einhorn scheme. The response rate was 67.89%. The most favorable results were found in the embryonal histologic
Publikováno v:
European Journal of Cancer. 35:S328